Injectable formulations of parp inhibitors and uses thereof
AssigneeZymeron Corporation
InventorsXu LI, Zhiguo ZHOU, Krishan KUMAR, Chunyan CAO
Life of this patent
Estimating the term…
Abstract
Described herein are injectable or infusible formulations of PARP inhibitors. In one aspect, the formulation comprises a PARP inhibitor and a cyclodextrin. The injectable or infusible PARP inhibitor-cyclodextrin formulation improves drug solubility, bioavailability, and therapeutic effectiveness. Also described herein are methods for treating oncological and non-oncological indications with injectable or infusible formulations of PARP inhibitors.
Claims14
A pharmaceutical composition comprising an amorphous powder of an inclusion complex comprising olaparib and a cyclodextrin (CD) derivative comprising hydroxypropyl-β-cyclodextrin or hydroxypropyl-γ-cyclodextrin in a mass ratio of olaparib to CD derivative of about 1:27 to about 1:1000.
An injectable or infusible pharmaceutical composition made by a process comprising:
- mixing olaparib with an aqueous solution of a cyclodextrin (CD) derivative comprising hydroxypropyl-β-cyclodextrin or hydroxypropyl-γ-cyclodextrin in a mass ratio of olaparib to CD derivative of about 1:27 to about 1:1000 to create a mixture of the olaparib and the CD derivative in an inclusion complex;
- freezing the mixture at −80° C.;
- lyophilizing the frozen mixture to create an amorphous powdered pharmaceutical composition;
- and
- dissolving the amorphous powdered pharmaceutical composition with a pharmaceutically acceptable solution for injection or infusion.
A method of treating, ameliorating, or inhibiting the progress of hemorrhagic shock, septic shock, or ovarian, prostate, breast, or pancreatic cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an amorphous powder of an inclusion complex comprising olaparib and a cyclodextrin (CD) derivative comprising hydroxypropyl-β-cyclodextrin or hydroxypropyl-γ-cyclodextrin in a mass ratio of olaparib to CD derivative of about 1:27 to about 1:1000.
A method of making an amorphous powdered pharmaceutical composition, the method comprising:
- mixing olaparib with an aqueous solution of a cyclodextrin (CD) derivative comprising hydroxypropyl-β-cyclodextrin or hydroxypropyl-γ-cyclodextrin in a mass ratio of olaparib to CD derivative of about 1:27 to about 1:1000 to create a mixture of the olaparib and the CD derivative in an inclusion complex;
- freezing the mixture at −80° C.;
- and
- lyophilizing the frozen mixture to create the amorphous powdered pharmaceutical composition.
Dependencies are inferred from the claim text.